Sanofi, Orano Med, and RadioMedix collaborate to develop radioligand therapies

Client(s) Sanofi

Jones Day represented and supported Sanofi's in-house team in connection with an exclusive licensing agreement with RadioMedix, Inc., and Orano Med, a subsidiary of the Orano Group. This collaboration between Sanofi, RadioMedix, and Orano Med focuses specifically on the late-stage project, AlphaMedix™ (212Pb-DOTAMTATE), being evaluated for the treatment of adult patients with somatostatin-receptor expressing neuroendocrine tumors (NETs), a rare cancer. Under the licensing agreement, Sanofi will be responsible for the global commercialization of AlphaMedix™, while Orano Med will be responsible for the manufacturing of AlphaMedix™ through its global industrial platform currently under development. Under the terms of the agreement, RadioMedix and Orano Med will receive an upfront payment of €100 million and up to €220 million in sales milestones and be eligible for tiered royalties.